Sana Biotechnology, Inc. (SANA)

7,56 +0,06 (+0,80%) Al cierre: 04:00PM EDT

Sana Biotechnology, Inc.

188 East Blaine Street
Suite 400
Seattle, WA 98102
United States
206 701 7914
https://www.sana.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 328

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Steven D. Harr M.D.	President, CEO & Director	1,04M	N/A	1970
Mr. Nathan Hardy M.B.A.	Executive VP & CFO	653,04k	N/A	1976
Mr. Snehal Patel	Senior VP & Chief Technical Officer	N/A	N/A	N/A
Mr. Bernard J. Cassidy J.D.	Executive VP, General Counsel & Corporate Secretary	491,39k	N/A	1955
Ms. Robin Andrulevich	Executive VP & Chief People Officer	N/A	N/A	1966
Dr. Edward Rebar Ph.D.	Head of Cell Engineering	N/A	N/A	1968
Mr. Paul Brunetta M.D.	Senior VP and Head of Clinical & Translational Science	N/A	N/A	N/A
Mr. Christian Hordo M.B.A.	Executive VP & Chief Business Officer	485,03k	N/A	1983
Dr. Sonja Schrepfer M.D., Ph.D.	Senior VP & Head of Hypoimmune Platform	N/A	N/A	1975
Dr. Terry Fry M.D.	Senior VP & Head of T Cell Therapeutics	N/A	N/A	1967

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Gobierno corporativo

El ISS Governance QualityScore de Sana Biotechnology, Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 2; Tablero: 7; Derechos de los accionistas: 8; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.